Journal article

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17

MM Vickers, CS Karapetis, D Tu, CJ O'Callaghan, TJ Price, NC Tebbutt, G Van Hazel, JD Shapiro, N Pavlakis, P Gibbs, J Blondal, U Lee, JM Meharchand, RL Burkes, SH Rubin, J Simes, JR Zalcberg, MJ Moore, L Zhu, DJ Jonker

Annals of Oncology | OXFORD UNIV PRESS | Published : 2013

Grants

Funding Acknowledgements

CSP Consultancy (Amgen, Astra Zeneca, Merck, Roche), Honoraria (Merck); TJP Consultancy (Merck); NCT Consultancy (Merck Serono), Research funding (Merck Serono); GVH Consultancy (Amgen, Merck Serono, Roche), Research funding (Merck Serono); JDS Consultancy (Merck); NO Consultancy (Merck) and Honoraria (Merck); PH Consultancy (Merck Serono); JS Research funding (Bristol-Myers Squibb); JRZ Research funding (Amgen, Merck Serono), DJJ Consultancy (Amgen, Bristol-Myers Squibb), Honoraria (Amgen, Bristol-Myers Squibb). The following authors have declared no conflicts of interest: MMV, DT, CJO, JBl, JMM, RLB, SHR, MJM, and LZ.